EGFR and non-small cell lung carcinoma: Indeed, EGFR TKIs are the recommended first‐line treatment for EGFR‐mutated NSCLC, with an associated median progression‐free survival (PFS) of 9.0–18.9 months.5, 6, 7, 8, 9